46 results about "Neurologic Dysfunctions" patented technology

The invention relates to a traditional Chinese medicine composition for treating ischemic stroke and a method and application thereof, and belongs to the technical field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition for treating ischemic stroke. The traditional Chinese medicine composition is prepared from the following raw materials: ginseng, pseudo-ginseng, radix polygoni multiflori preparata, ligusticum wallichii, safflower carthamus, salvia miltiorrhiza, hawthorn, loranthus parasiticus, longspur epimedium, radix puerariae, cornu bubali, ginseng leaves, rhizoma acori graminei and borneol. According to the preparation method disclosed by the invention, the ligusticum wallichii and compound bacteria consisting of lactobacillus plantarum, bacillus subtilis and coriolus hirsutus are fermented, so that more laccase and active substances are generated in a fermented product, and then the fermented product is subjected to compound enzyme treatment, so that the processed ligusticum wallichii is better in medicine effect, and the curative effect of the ligusticum wallichii is improved. Therefore, the treatment effect of the traditional Chinese medicine composition for treating ischemic stroke is enhanced, neurological dysfunction caused by cerebral ischemia can be remarkably relieved, and the traditional Chinese medicine composition has a good protection effect on ischemic stroke nerve injury.

The invention provides a nerve regulation and control system and method for a spinal cord ventral epidural region, and the system employs a microprocessor to generate multiple paths of pulse width modulation signals, and drives a voltage-controlled current source after amplitude adjustment. Stimulation current with adjustable frequency, pulse width and amplitude is output to act on a spinal cord ventral nerve structure. Real-time monitoring of stimulation current of each channel is realized through combination of voltage sampling and a single-pole multi-throw analog switch, feedback information of a body position, myoelectricity, pressure and other multi-mode sensors is fused, a closed-loop control mechanism is constructed, and dynamic adjustment and individualized optimization of electrical stimulation parameters are realized. The system has the advantages of being more accurate in electrical stimulation positioning, more sensitive in response, more intelligent in control and the like, and is suitable for intelligent rehabilitation intervention in scenes of spinal cord injury, cerebral palsy, neurological dysfunction and the like.

An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The invention provides a medicine for improving neurological dysfunction after cerebral ischemia, and relates to the technical field of biological medicine and molecular biology, and the medicine comprises the following steps: S1, preparing materials; s2, cell injury model and intervention test; s3, cell activity and oxidative stress index detection. The invention provides application of combination of baicalein and ferulic acid in preparation of a medicine for improving neurological dysfunction after cerebral ischemia, the embodiment of the invention proves that combination of baicalein and ferulic acid can improve neurological dysfunction after cerebral ischemia by reducing cerebral infarction area, resisting oxidation, inhibiting inflammatory response and the like, and test data shows that compared with a model group, the combination of baicalein and ferulic acid has the advantages that the combination of baicalein and ferulic acid has a good application prospect. White cerebral infarction areas of the rats in the administration group are reduced; after the palmitic acid treatment, the baicalein and ferulic acid combined administration group can promote the proliferation of SH-SY5Y nerve cells; after baicalein and ferulic acid are combined for treatment, the MDA level in damaged cells is remarkably reduced, and the SOD and GSH levels are remarkably increased, so that the baicalein and ferulic acid have the effects of resisting oxidation, inhibiting inflammation and protecting nerve cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Chi3l1 as a target spot in preparation of a medicine for preventing or treating secondary brain injury after cerebral hemorrhage. By integrating space transcriptomics and a mononuclear RNA sequencing technology, the spatial heterogeneity and cell type specificity of gene expression in ICH afterbrain tissue are deeply analyzed, a group of astrocyte subgroups AST1 with neuritis existing around hematoma in the acute stage after cerebral hemorrhage is identified, Chi3l1 is determined as a key inflammatory effect factor of the AST1 subgroups, and the AST1 subgroups with neuritis are used as the key inflammatory effect factor of the AST1 subgroups. And the influence of the gene on the phenotypic transformation of astrocytes and microglial cells is verified. The discovery provides an important theoretical basis for developing a treatment strategy of targeting Chi3l1, and is expected to improve neuroinflammatory response and neurological dysfunction after ICH by regulating and controlling expression of the AST1 subgroup and Chi3l1, and opens up a new direction for treatment of ICH.

The present invention relates to a neuroelectrophysiological monitoring device and method for use during spinal surgery. A neuroelectrophysiological monitoring device for use during spinal surgery, the monitoring device comprising an electroencephalogram (EEG) monitoring module, an intraoperative neural stimulation monitoring module, a synchronization signal module, and an abnormal electrophysiological event warning module. The EEG monitoring module is used to receive the patient's intraoperative EEG data, the intraoperative neural stimulation monitoring module is used to monitor evoked potential data and to perform SEP and / or MEP stimulation on the patient during surgery, the synchronization signal module is used to synchronize EEG data and evoked potential data, and the abnormal electrophysiological event warning module warns of abnormal electrophysiological events based on EEG data and evoked potential data. The technical solution adopted by the present invention can realize intraoperative neural monitoring and can detect new neural dysfunctions early so as to correct the causes in time. The EEG monitoring method of the present invention can also accurately record adverse reactions occurring during surgery, thereby performing retrospective analysis.

The invention discloses an application of intestinal microbial flora in preparation of a microecological preparation for treating gas explosion brain injury, and the neuroprotective effect of fecal microbial transplantation on GE-induced TBI rats, including neurological dysfunction, neuropathological change and neuroinflammation, is researched by adjusting a microflora-intestinal tract-brain axis. According to the invention, a model of intestinal flora imbalance and brain injury of male rats is established by using a fecal microbial transplantation technology, and then non-targeted metabonomics and microbial diversity analysis are carried out to explore bacteria with potential functions. Meanwhile, the intestinal microbiota composition, the intestinal and brain barrier functions and the number of regulatory T cells of the brain are evaluated. A potential anti-inflammatory mechanism determined by integrating microbiome and metabolome analysis relates to a peripheral immune pathway, and a promising strategy is provided for relieving GE-induced TBI.

The invention relates to the technical field of new application of medicines, in particular to application of G15 to treatment of white matter injury based on promotion of cerebrovascular generation, and finds that the G15 has the effect of promoting cerebrovascular generation, can promote myelination insufficiency caused by hypoxia in the early development stage and can improve neurological dysfunction caused by hypoxia, and the G15 has the effect of promoting cerebrovascular generation. Moreover, myelin sheath regeneration of a local demyelination area after the adult can be promoted, so that the effect of directly treating the white matter injury from the pathological aspect is achieved. The invention provides a new application of G15 in treating white matter injury and long-term neurological dysfunction by promoting cerebrovascular generation.

The invention relates to the technical field of medical equipment, and particularly discloses a multifunctional inspectoscope for pediatric neurology, which comprises a bottom plate, a small ladder, a box body and a stand column are fixedly mounted on the bottom plate, the box body is positioned between the small ladder and the stand column, a lower chamber and an upper chamber are arranged in the box body, and a test port is formed in the top of the box body; two turntables are rotatably arranged on the lower inner wall of the upper cavity, palm rests and track mechanisms are arranged on the upper sides of the two turntables, supporting rods are slidably arranged on the tops of the two turntables, and a plurality of detection mechanisms are installed on the side portions of the two supporting rods; the rotatable detection mechanism can move around the leg, so that the neurological function states of different muscle groups can be evaluated more comprehensively, the type and degree of neurological dysfunction can be diagnosed more accurately through more comprehensive evaluation, and the accuracy of a detection result is improved.

Described herein are systems and methods used to evaluate individuals such as children for behavioral disorders, developmental delays, and neurological impairments. An exemplary method includes receiving input data of an individual related to a behavioral disorder, neurological impairment, or developmental delay, and evaluating the input data using an evaluation module comprising at least one machine learning model, thereby generating an evaluation result, where the machine learning model comprises one or more decision threshold hyperparameters that differentiate between a positive evaluation, negative evaluation, and an indeterminate evaluation with respect to a presence or an absence of the behavioral disorder, neurological impairment, or developmental delay.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

A method of treatment of a subject suffering from autonomic dysfunction due to opioid use is described. The autonomic dysfunction can be determined by, for example, detecting genetic damage, such as DNA hypermethylation, measuring catecholamine concentrations, collecting vitals data, and / or surveys. The method of treatment can include administering a partial opioid agonist, such as buprenorphine.

The present invention addresses the problem of providing: a biomarker for determining cognitive impairment or nerve function disorder in an early stage with high accuracy; and others.　In the present invention, a drebrin metabolite peptide (iMADP) selected from the below-mentioned peptides (i) to (iii) is used as a biomarker for determining cognitive impairment or nerve function disorder. (i) A peptide comprising the amino acid sequence represented by SEQ ID NO: 4; (ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 5; and (iii) a peptide which comprises an amino acid sequence having a structure such that one or more amino acid residues are deleted, substituted, and / or added in the amino acid sequence represented by SEQ ID NO: 4 or SEQ ID NO: 5.

Systems and methods are provided for delivering closed-loop or partially closed-loop baroreflex activation therapy (BAT) to treat conditions associated with autonomic dysfunction. A pulse generator delivers stimulation while physiological data, such as ECG, heart rate variability, bioimpedance, and physical activity levels, is collected from one or more sensors. The data is analyzed to assess autonomic nervous system activity, and stimulation parameters are dynamically adjusted in response. In some embodiments, adjustments are made on a beat-to-beat basis using ECG input. Artificial intelligence algorithms may be used to predict patient-specific responses, optimize therapy, and evaluate effectiveness. The method may further include integrating patient-reported symptoms, wirelessly transmitting data, or adjusting stimulation duty cycle based on time of day. The system may further incorporate patient-reported symptoms, a clinician dashboard for remote monitoring, and a multi-channel lead. Stimulation may be delivered non-invasively or via an implantable device.

The application provides a kind of affected side spatial stratification activation and multi-modal unilateral spatial neglect (USN) cognitive function evaluation and training intelligent system, aiming at solving the pain points such as low efficiency of evaluation, training homogeneity, effect difficult to transfer in USN patient rehabilitation, and building a whole-process intelligent rehabilitation system of "accurate evaluation-personalized training-dynamic optimization-effect transfer". Through the combination of rapid quantitative evaluation system, behavior data and electroencephalogram signal, the objective grading of USN severity is realized, which gets rid of artificial dependence and greatly improves the evaluation efficiency and accuracy; through the whole-process automatic operation and machine learning self-adaptive optimization, the operation cost of clinical personnel is reduced, the rehabilitation effect is traceable and evaluable, and an accurate and personalized intelligent rehabilitation system is built, which provides a whole-process solution for USN patients and has important significance for promoting the intelligent development of post-stroke neurological dysfunction rehabilitation.

The invention discloses an application of isosteviol containing a hydroxamic acid group and a steviol derivative in nerve injury protection, relates to the field of nerve injury protection medicines, and aims to provide an HDAC6 inhibitor capable of improving nerve dysfunction. Isosteviol and steviol derivatives containing hydroxamic acid groups are applied in the field of nerve injury protection, especially in the treatment of neurodegenerative diseases. The isosteviol and the steviol derivative containing the hydroxamic acid group enhance the antioxidant defense capability of cells and reduce oxidative stress induced cell apoptosis by regulating and controlling an Nrf2 / HO-1 signal channel, a Bcl2 / Bax signal axis and an HDAC6 / Ac-Tubulin microtubule stabilizing signal axis, so that the neuroprotective effect is achieved. Important theoretical support is provided for development of tetracyclic diterpenoid natural compounds in the field of neuroprotection, and the application prospect of the tetracyclic diterpenoid natural compounds in treatment of neurodegenerative diseases is expanded.

Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and / or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and / or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.

The invention discloses a construction method of a microglial cell conditional knock-down dynactin animal model, which comprises the following steps: selecting a Dctn1LoxP gene knock-in mouse, hybridizing the Dctn1LoxP gene knock-in mouse with a Cx3cr1-Cre transgenic mouse, and carrying out three rounds of breeding to obtain a genotype Dctn1LoxP / LoxP; a mouse of Cx3cr1-Cre; the expression of Cre recombinase is driven by a Cx3cr1 gene promoter, and the 2nd to 4th exons of the Dctn1 gene are cut, so that the knockout of p150Glue and the reduction of the protein levels of other subunits of dynactin are realized. The model is strong in specificity and high in knock-down efficiency, animals show microglial cell morphology abnormity and movement coordination function defects, the model can be used for researching the influence of dynactin on microglial cell neurobiological functions, and a reliable tool is provided for pathogenesis exploration and drug screening of related neurological dysfunction.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.

The invention provides a method of determining whether a subject has a neurological dysfunction associated with a signal in a particular electroencephalogram (EEG) or magnetoencephalogram (MEG) frequency range, the method comprising: obtaining an EEG power spectrum from the subject; and obtaining a metric quantifying the magnitude of power in particular frequency range metric quantifying the power in the power spectrum in the particular frequency range, wherein the metric summarises the power in said frequency range corrected using an estimate of the power in said frequency range that is attributable to background signal that is specific to said frequency range, wherein the metric is indicative of the presence and / or severity and / or direction of a neurological dysfunction. Related methods and devices are also described.

The invention relates to the technical field of biological medicines, in particular to application of piperine in preparation of a medicine for treating cerebral ischemia-reperfusion injury and a verification method, and the application of the piperine in preparation of the medicine for treating cerebral ischemia-reperfusion injury is confirmed for the first time. It is shown that the piperine can be used for treating the new indications of the cerebral ischemic stroke reperfusion injury, the current experimental result provides powerful support and basis for wide application of the new indications of the piperine, and the treatment effect of the piperine on the cerebral ischemic reperfusion injury is evaluated; on a mouse cerebral ischemia reperfusion model, the piperine can reduce the volume of mouse cerebral infarction induced by cerebral ischemia reperfusion, relieve neurological dysfunction, increase cerebral blood flow, relieve brain injury and improve blood-brain barrier dysfunction, and the piperine is used for preparing the medicine for treating cerebral arterial thrombosis reperfusion injury. The invention develops a new medical application of piperine in treating cerebral ischemia-reperfusion injury.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating cerebral arterial thrombosis, and relates to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of Yulangsan, 5-30 parts of panax japonicus, 5-30 parts of ruta graveolens, 5-30 parts of camphorwood, 5-30 parts of millettia japonica, 5-30 parts of costus root, 5-30 parts of rhizoma curculiginis, 5-30 parts of clinopodium herb, 5-30 parts of white hyacinth bean and 5-30 parts of radix puerariae. The whole formula treats both qi and blood, regulates phlegm and blood stasis, is reasonable in compatibility of the medicines, and has the effects of tonifying qi and activating blood, dispersing blood stasis and dredging collaterals, clearing heat and dissipating blood stasis, restoring consciousness and dredging collaterals, and tonifying spleen and warming kidney. The traditional Chinese medicine composition can relieve cerebral infarction and encephaledema, improve neurological dysfunction, inhibit neuronal apoptosis and regulate inflammatory response to relieve inflammatory damage of brain tissue, and a good treatment effect on cerebral arterial thrombosis model rats is achieved. The traditional Chinese medicine composition provides a new choice for development of medicines for treating cerebral arterial thrombosis.

The present application provides a nerve regulation system and method for the ventral epidural region of the spinal cord, wherein the nerve regulation system for the ventral epidural region of the spinal cord generates a multi-channel pulse width modulation signal by using a microprocessor, drives a voltage-controlled current source after amplitude adjustment, and outputs a stimulation current with adjustable frequency, pulse width and amplitude to act on the ventral nerve structure of the spinal cord. Real-time monitoring of the stimulation current of each channel is realized by combining voltage sampling and single-pole multi-throw analog switches, while the feedback information of multiple modal sensors such as body position, electromyography and pressure is integrated to construct a closed-loop control mechanism, realize dynamic adjustment and individual optimization of the electric stimulation parameters. The precise activation ability of motor and autonomic nerve function is enhanced, and the present application has the advantages of more accurate electric stimulation positioning, more sensitive reaction, more intelligent control and the like, and is suitable for intelligent rehabilitation intervention in scenes such as spinal cord injury, cerebral palsy, and nerve dysfunction.

One variation of a method for modeling neurological development includes: aggregating electroencephalography (EEG) data that comprise multiple EEG signals of each user in a set of users, EEG signals of each user recorded on multiple distinct dates, the set of users comprising a plurality of users of various known neurological statuses; identifying a synchronization pattern trend within the EEG data of the set of users; and correlating the synchronization pattern trend with neurological development within the set of users.

The invention relates to the technical field of medical animal disease models, in particular to a method for establishing a gene point mutation non-human primate model.According to the method, editing is conducted through a CRISPR / Cas9 gene editing system, and finally a non-human primate model carrying CHD8c.3724Cgt is obtained; according to the cynomolgus monkey with T (p.Arg1242Ter) point mutation, different types of point mutations occur at the 3724th basic group of the CHD8 gene, the mutation of T enables arginine (Arg) at the 1242nd site to be replaced by a termination codon to form truncated protein, so that the dosage of CHD8 protein haploid coded by the gene is insufficient. The animal model for simulating human CHD8 mutation related nervous system diseases is constructed and can be used as an ideal research model for researching autism related phenotypes caused by insufficient haplodose, and a foundation is laid for revealing a neurological dysfunction mechanism and exploring a potential treatment strategy.

One variation of a method for modeling neurological development includes: aggregating electroencephalography (EEG) data that comprise multiple EEG signals of each user in a set of users, EEG signals of each user recorded on multiple distinct dates, the set of users comprising a plurality of users of various known neurological statuses; identifying a synchronization pattern trend within the EEG data of the set of users; and correlating the synchronization pattern trend with neurological development within the set of users.

The invention provides a traditional Chinese medicine composition for promoting neural function recovery, an AnnaoPingchong pill and a preparation method of the AnnaoPingchong pill. The traditional Chinese medicine composition comprises the following active ingredient raw materials in parts by weight: 25-40 parts of raw fossil fragments, 25-40 parts of raw oysters, 10-25 parts of radix cyathulae, 5-18 parts of tribulus terrestris, 8-20 parts of uncaria rhynchophylla, 8-18 parts of rhizoma alismatis, 10-20 parts of moutan bark, 10-20 parts of cape jasmine, 8-25 parts of scutellaria baicalensis, 10-25 parts of radix paeoniae alba, 5-15 parts of raw rhubarb, 3-12 parts of liquorice, 1-5 parts of lotus plumule, 0.1-0.5 part of calculus bovis factitius and 0.01-0.05 part of artificial borneol. The traditional Chinese medicine composition follows the medication principle of'monarch, minister, assistant and guide 'of traditional Chinese medicines, can lower qi, quiet qi and blood and calm vitality, and has a good treatment effect on neurological dysfunction after cerebral hemorrhage.

Provided are methods of detecting concussion-level, neurologic dysfunction in a subject at risk of having developed concussion-level, neurologic dysfunction following exposure to repetitive, non-concussive head insults. Additionally provided are methods for preventing concussion-level, neurologic dysfunction in a subject at risk of developing such neurologic dysfunction.